To support Eagle Genomics’ growth plans, the company has raised $1m within 3 weeks of the launch of its latest investment round, in a first close.

Angel Academe has invested in doppel, a wristband shown to reduce stress. It works by creating a silent vibration on the inside of your wrist which feels just like the ‘lub-dub’ of a heartbeat. Slower rhythms are calming, and faster rhythms help you feel focused – like music. You can use it to stay calm under pressure, focus on the task ahead of you, and keep going when you need to.

Atelerix, a Cambridge and Newcastle, UK-based spin-out from the University of Newcastle and creators of an innovative cell encapsulation technology, closed a round of funding of undisclosed amount.

A spinout company whose technology could save the lives of thousands of dialysis patients has secured £500,000 from Mercia Fund Managers, in the first investment deal since Mercia’s partnership with the University of Edinburgh was announced in November 2017.

The UCL Technology Fund, UK Innovation & Science Seed Fund (UKI2S), alongside support from Innovate UK, have invested in UCL spinout company Glialign Ltd, which is developing a novel cell therapy for peripheral nerve repair. 

Jellagen, a pioneer in marine biotechnologies based in Wales, has closed a £3.8m funding round led by Newable Private Investing, the Development Bank of Wales, and angel investors. Newable Private Investing is one of the UK’s leading private investment groups, providing support to cutting-edge start-ups.

London-based investment management firm, Downing LLP, and BioScience Managers Limited, the international healthcare investment firm and advisers to the Downing FOUR VCT, have invested £1.14 million in Wales-based ADC Biotechnology Ltd.

ADC Biotechnology is creating innovative new technology, which aims to speed up, simplify and significantly lower the costs of the processes involved in the production of new antibody drug 

GSK and Orchard Therapeutics have announced a strategic agreement, under which GSK will transfer its portfolio of approved and investigational rare disease gene therapies to Orchard, securing the continued development of the programmes and access for patients. This acquisition strengthens Orchard’s position as a global leader in gene therapy for rare diseases. GSK will continue to invest in the development of its platform capabilities in cell and gene therapies, with a focus on oncology.

Touch Biometrix, a UK company aiming to change the way we interact with technology for user authentication are pleased to announce they have received seed investment from Deepbridge Capital.

LNC Therapeutics, a French biotech company specializing in research and development for gut microbiome-based drugs, has announced the appointment of Dr. Georges Rawadi as its new CEO.  Jean-Luc Treillou, his predecessor, will become Chairman of the Board of Directors on July 1st.

Zelluna Immunotherapy, the biotechnology company specializing in T-cell receptor (TCR) immunotherapies targeting a broad range of solid cancers with a high unmet medical need, has announced the appointment of Arjan Roozen as chief technology officer (CTO). 

Pharmacy2U, the UK’s largest NHS online pharmacy, has secured a further £40 million investment to support the rapid growth of its online